AR061273A1 - THERAPY USING CITOCINE INHIBITORS - Google Patents
THERAPY USING CITOCINE INHIBITORSInfo
- Publication number
- AR061273A1 AR061273A1 ARP070102483A ARP070102483A AR061273A1 AR 061273 A1 AR061273 A1 AR 061273A1 AR P070102483 A ARP070102483 A AR P070102483A AR P070102483 A ARP070102483 A AR P070102483A AR 061273 A1 AR061273 A1 AR 061273A1
- Authority
- AR
- Argentina
- Prior art keywords
- attached
- forming
- target protein
- orientation
- variables
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos para tratar, prevenir, modificar y manejar las enfermedades mediadas con citocina o las enfermedades relacionadas, que comprenden la administracion de un compuesto, tal como un inhibidor de citocina, solo o en combinacion con terapéuticos conocidos. Composiciones farmacéuticas y regímenes de dosis usando los compuestos descritos. Uso de compuestos como se describen en este documento, opcionalmente en conjuncion con otras terapias, para el tratamiento de enfermedades autoinmunes, enfermedades inflamatorias, enfermedades cardiovasculares y cáncer. Reivindicacion 1: Un método para tratar un trastorno mediado por una o más citocinas, caracterizado porque comprende administrar a un sujeto en necesidad de tal tratamiento una cantidad terapéuticamente efectiva de un compuesto, en donde el compuesto se selecciona de: a) G-N(H)X-Ar-L-Q en donde las variables G, X, Ar, L, y Q son como se definieron en las Listas II, III o IV; b) G-X-N(H)Ar-L-Q en donde las variables G, X, Ar, L, y Q son como se definieron en las Listas V, VI, o VII; c) G-anillo-Ar-L-Q, en donde las variables G, anillo, Ar, L, y Q son como se definieron en la Lista VIII; d) formula (2) en donde las variables G, X', Ar, L, y Q son como se definieron en la Lista IX, e) formula (3) en donde las variables G, L1, L2, L3, A, Ar, y Q son como se definieron en la Lista X; f) formula (4) en donde las variables G, X, Y, L1, L2, A, B, D, E y Q son como se definieron en la Lista XI, g) un compuesto que comprende: una porcion de direccion, TM que comprende por lo menos un grupo amida que tiene un NH amida, la porcion de direccion capaz de formar uno o más enlaces de hidrogeno con una proteína objetivo, y en donde la porcion de direccion no es un grupo urea; una porcion de expansion de cavidad, PEM unida directamente a la porcion de direccion, la porcion de expansion de cavidad comprende una porcion plana unida a una porcion hidrofobica no plana voluminosa, la porcion no plana forma interacciones hidrofobicas con la proteína objetivo; y una porcion de orientacion, OM que comprende una porcion hidrofobica plana y unida a un átomo diferente de la porcion de direccion que la porcion de expansion de cavidad, la porcion de orientacion capaz de formar una interaccion aromática p-p o borde a cara con la proteína objetivo; h) un compuesto que comprende una porcion de direccion, TM, que comprende un grupo amida que tiene un NH amida y carbonilo, la porcion de direccion capaz de formar uno o más enlaces de hidrogeno con una proteína objetivo; una porcion de expansion de cavidad, PEM, unida directamente a la porcion de direccion, la porcion de expansion de cavidad comprende una porcion plana unida a una porcion hidrofobica no plana voluminosa, en donde la porcion no plana es capaz de formar interacciones hidrofobicas con la proteína objetivo; una porcion de orientacion, OM, que comprende un anillo piridilo y unida a un átomo diferente de la porcion de direccion que la porcion de expansion de cavidad, en donde la porcion de orientacion es capaz de formar interacciones hidrofobicas con la proteína objetivo; y una porcion de anclaje, AM, unida indirectamente a la porcion de orientacion por una porcion conectora, L, en donde la porcion de anclaje es capaz de formar por lo menos una interaccion de enlace de hidrogeno con una cavidad de union a ATP de la proteína objetivo; i) un compuesto que comprende: una porcion de direccion, TM, que comprende un NH amida y carbonilo, la porcion de direccion capaz de formar uno o más enlaces de hidrogeno con una proteína objetivo; una porcion de expansion de cavidad, PEM, unida directamente al carbonilo de la porcion de direccion, la porcion de expansion de cavidad comprende una porcion plana unida a una porcion hidrofobica no plana voluminosa, en donde la porcion no plana capaz de formar interacciones hidrofobicas con la proteína objetivo; una porcion de orientacion, OM, que comprende un anillo arilo o heteroarilo de 6 miembros y unida al NH de la porcion de direccion, en donde la porcion de orientacion es capaz de formar interacciones hidrofobicas con la proteína objetivo; una porcion conectora, L, unida a un átomo diferente de la porcion de orientacion que la porcion de direccion, en donde la porcion conectora comprende una porcion heteroarilo de 5 miembros y el punto de union en la porcion heteroarilo es un átomo de carbono; y una porcion de anclaje, AM, unida a la porcion de orientacion por la porcion conectora, L, en donde la porcion de anclaje es capaz de formar por lo menos una interaccion de enlace de hidrogeno con una cavidad de union a ATP de la proteína objetivo; o un estereoisomero, tautomero, solvato, profármaco, o sales farmacéuticamente aceptable de cualquiera de uno o más de (a)-(i).Methods for treating, preventing, modifying and managing cytokine-mediated diseases or related diseases, which comprise the administration of a compound, such as a cytokine inhibitor, alone or in combination with known therapeutics. Pharmaceutical compositions and dose regimens using the compounds described. Use of compounds as described herein, optionally in conjunction with other therapies, for the treatment of autoimmune diseases, inflammatory diseases, cardiovascular diseases and cancer. Claim 1: A method of treating a disorder mediated by one or more cytokines, characterized in that it comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound, wherein the compound is selected from: a) GN (H) X-Ar-LQ where the variables G, X, Ar, L, and Q are as defined in Lists II, III or IV; b) G-X-N (H) Ar-L-Q where the variables G, X, Ar, L, and Q are as defined in Lists V, VI, or VII; c) G-ring-Ar-L-Q, where the variables G, ring, Ar, L, and Q are as defined in List VIII; d) formula (2) where the variables G, X ', Ar, L, and Q are as defined in List IX, e) formula (3) where the variables G, L1, L2, L3, A, Ar, and Q are as defined in List X; f) formula (4) wherein the variables G, X, Y, L1, L2, A, B, D, E and Q are as defined in List XI, g) a compound comprising: a direction portion, TM comprising at least one amide group having an NH amide, the address portion capable of forming one or more hydrogen bonds with a target protein, and wherein the address portion is not a urea group; a cavity expansion portion, PEM attached directly to the direction portion, the cavity expansion portion comprises a flat portion attached to a bulky non-planar hydrophobic portion, the non-plane portion forms hydrophobic interactions with the target protein; and an orientation portion, OM comprising a flat hydrophobic portion and attached to an atom different from the direction portion than the cavity expansion portion, the orientation portion capable of forming a pp or edge-to-face aromatic interaction with the protein objective; h) a compound comprising a direction portion, TM, comprising an amide group having an NH amide and carbonyl, the direction portion capable of forming one or more hydrogen bonds with a target protein; a cavity expansion portion, PEM, directly attached to the direction portion, the cavity expansion portion comprises a flat portion attached to a bulky non-planar hydrophobic portion, wherein the non-plane portion is capable of forming hydrophobic interactions with the target protein; an orientation portion, OM, comprising a pyridyl ring and attached to an atom different from the direction portion than the cavity expansion portion, wherein the orientation portion is capable of forming hydrophobic interactions with the target protein; and an anchor portion, AM, indirectly attached to the orientation portion by a connector portion, L, wherein the anchor portion is capable of forming at least one hydrogen bonding interaction with an ATP binding cavity of the target protein; i) a compound comprising: a direction portion, TM, comprising an NH amide and carbonyl, the direction portion capable of forming one or more hydrogen bonds with a target protein; a cavity expansion portion, PEM, directly attached to the carbonyl of the steering portion, the cavity expansion portion comprises a flat portion attached to a bulky non-planar hydrophobic portion, wherein the non-flat portion capable of forming hydrophobic interactions with the target protein; an orientation portion, OM, comprising a 6-membered aryl or heteroaryl ring and attached to the NH of the address portion, wherein the orientation portion is capable of forming hydrophobic interactions with the target protein; a connecting portion, L, attached to an atom different from the orientation portion than the steering portion, wherein the connecting portion comprises a 5-membered heteroaryl portion and the point of attachment in the heteroaryl portion is a carbon atom; and an anchor portion, AM, attached to the orientation portion by the connector portion, L, wherein the anchor portion is capable of forming at least one hydrogen bonding interaction with an ATP binding cavity of the protein objective; or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salts of any one or more of (a) - (i).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81226806P | 2006-06-09 | 2006-06-09 | |
US83307806P | 2006-07-24 | 2006-07-24 | |
US83527006P | 2006-08-03 | 2006-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061273A1 true AR061273A1 (en) | 2008-08-13 |
Family
ID=38832677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102483A AR061273A1 (en) | 2006-06-09 | 2007-06-08 | THERAPY USING CITOCINE INHIBITORS |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2035005A4 (en) |
AR (1) | AR061273A1 (en) |
AU (1) | AU2007257959A1 (en) |
CA (1) | CA2691214A1 (en) |
CL (1) | CL2007001670A1 (en) |
PE (1) | PE20080935A1 (en) |
TW (1) | TW200814998A (en) |
WO (1) | WO2007146712A2 (en) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101426093B1 (en) | 2006-02-10 | 2014-08-01 | 서미트 코포레이션 피엘씨 | Treatment of duchenne muscular dystrophy |
US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
CL2007002866A1 (en) | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | COMPOUNDS DERIVED FROM 6-SUBSTITUTES-2- (BENCIMIDAZOLIL) PURINA AND PURINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF AUTOIMMUNE DISEASES, INFLAMMATORY DISEASE, DISEASE MEDIATED BY M |
US7915268B2 (en) | 2006-10-04 | 2011-03-29 | Wyeth Llc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
US8440832B2 (en) * | 2007-07-13 | 2013-05-14 | Board Of Regents, The University Of Texas System | Heterocyclic modulators of cannabinoid receptors |
LT2170396T (en) | 2007-08-03 | 2017-03-10 | Summit (Oxford) Limited | Drug combinations for the treatment of duchenne muscular dystrophy |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
US20110230497A1 (en) * | 2008-11-07 | 2011-09-22 | H. Lundbeck A/S | Biologically active amides |
CA2764387A1 (en) | 2009-06-05 | 2010-12-09 | Link Medicine Corporation | Aminopyrrolidinone derivatives and uses thereof |
WO2011063076A1 (en) * | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
EA026094B1 (en) * | 2009-12-23 | 2017-03-31 | Рациофарм Гмбх | Solid dosage form of ticagrelor |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
JP6155187B2 (en) * | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | Polysubstituted aromatic compounds as inhibitors of thrombin |
SG184987A1 (en) | 2010-04-22 | 2012-11-29 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
AR081626A1 (en) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081331A1 (en) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
GB2515941A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
EA201490836A1 (en) | 2011-10-21 | 2014-11-28 | Эббви Инк. | COMBINATION TREATMENT (FOR EXAMPLE, WITH ABT-072 OR ABT-333) WITH THE HELP OF DAA FOR USE WHEN TREATING HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
CN108354933A (en) | 2013-03-15 | 2018-08-03 | 维颂公司 | The pharmaceutical applications of polysubstituted aromatic compounds as serpin |
WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
PL3925607T3 (en) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CA2960790A1 (en) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
AU2015360416A1 (en) | 2014-12-10 | 2017-06-08 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
LT3261639T (en) | 2015-02-27 | 2022-11-25 | Verseon International Corporation | Substituted pyrazole compounds as serine protease inhibitors |
CN107921046B (en) * | 2015-06-12 | 2022-10-14 | 格林威治大学 | Triazine derivatives as interferon-gamma inhibitors |
EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3377488T2 (en) | 2015-11-19 | 2023-02-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
EP3390396B1 (en) | 2015-12-15 | 2022-07-06 | Astrazeneca AB | Isoindole compounds |
SG11201805300QA (en) | 2015-12-22 | 2018-07-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
RU2018132559A (en) | 2016-02-16 | 2020-03-17 | Массачусетс Инститьют Оф Текнолоджи | BINDING MOLECULES FOR MAX AS MYC MODULATORS AND THEIR APPLICATIONS |
CN109689063A (en) | 2016-04-28 | 2019-04-26 | 埃默里大学 | Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses |
ES2906460T3 (en) | 2016-05-06 | 2022-04-18 | Incyte Corp | Heterocyclic compounds as immunomodulators |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CN115105601A (en) * | 2016-06-08 | 2022-09-27 | 投资支持有限公司 | Pharmaceutical combination for the treatment of cancer |
CA3028685A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2941716T3 (en) | 2016-08-29 | 2023-05-25 | Incyte Corp | Heterocyclic compounds as immunomodulators |
EP3558997B1 (en) | 2016-12-20 | 2021-01-27 | AstraZeneca AB | Amino-triazolopyridine compounds and their use in treating cancer |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
HRP20221216T1 (en) | 2016-12-22 | 2022-12-23 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2934230T3 (en) | 2016-12-22 | 2023-02-20 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
CA3063729A1 (en) * | 2017-05-15 | 2018-11-22 | Recurium Ip Holdings, Llc | Analgesic compounds |
WO2018229155A1 (en) | 2017-06-14 | 2018-12-20 | Astrazeneca Ab | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
CN111646986B (en) * | 2017-09-13 | 2022-03-25 | 厦门稀土材料研究所 | Nicotinic acid derivative and preparation method and application thereof |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CA3128468A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
CN112020500A (en) | 2017-12-22 | 2020-12-01 | 拉文纳制药公司 | Aminopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase |
FI3774791T3 (en) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterocyclic compounds as immunomodulators |
CN112752756A (en) | 2018-05-11 | 2021-05-04 | 因赛特公司 | Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators |
US11292782B2 (en) | 2018-11-30 | 2022-04-05 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN111825605B (en) * | 2019-04-19 | 2023-03-31 | 中国科学院上海药物研究所 | Aryl ketone amide compound and preparation method and application thereof |
TW202115059A (en) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Salts of a pd-1/pd-l1 inhibitor |
AU2020357514A1 (en) | 2019-09-30 | 2022-04-07 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
CA3159766A1 (en) * | 2019-11-05 | 2021-05-14 | Dermira, Inc. | Mrgprx2 antagonists for the treatment of inflammatory disorders |
WO2021096849A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
TW202128675A (en) | 2019-12-06 | 2021-08-01 | 美商維泰克斯製藥公司 | Substituted tetrahydrofurans as modulators of sodium channels |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
CN113209112B (en) * | 2021-02-06 | 2021-12-24 | 广州市朝利良生物科技有限公司 | Novel coronavirus resistant medicine based on ACE2 and S protein binding target and application thereof |
US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1392661A1 (en) * | 2001-05-16 | 2004-03-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
AU2004270733B2 (en) * | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
-
2007
- 2007-06-06 WO PCT/US2007/070547 patent/WO2007146712A2/en active Application Filing
- 2007-06-06 CA CA2691214A patent/CA2691214A1/en not_active Abandoned
- 2007-06-06 AU AU2007257959A patent/AU2007257959A1/en not_active Abandoned
- 2007-06-06 EP EP07798190A patent/EP2035005A4/en not_active Withdrawn
- 2007-06-08 PE PE2007000714A patent/PE20080935A1/en not_active Application Discontinuation
- 2007-06-08 AR ARP070102483A patent/AR061273A1/en unknown
- 2007-06-08 TW TW096120764A patent/TW200814998A/en unknown
- 2007-06-08 CL CL2007001670A patent/CL2007001670A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20080935A1 (en) | 2008-08-02 |
TW200814998A (en) | 2008-04-01 |
CL2007001670A1 (en) | 2008-01-18 |
EP2035005A2 (en) | 2009-03-18 |
WO2007146712A2 (en) | 2007-12-21 |
AU2007257959A1 (en) | 2007-12-21 |
CA2691214A1 (en) | 2007-12-21 |
WO2007146712A3 (en) | 2008-11-27 |
EP2035005A4 (en) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061273A1 (en) | THERAPY USING CITOCINE INHIBITORS | |
JP2009506048A5 (en) | Condensed imidazolo derivatives for inhibition of aldosterone synthase and aromatase | |
MX2021015605A (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors. | |
AR061101A1 (en) | FENIL-TRIAZOLIL- METOXI-ARILO COMPOSITE, ITS USE FOR THE MANUFACTURE OF A PHARMACEUTICAL MEDICINAL COMPOSITION AND COMPOSITION | |
AR104388A1 (en) | INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | |
CR20220456A (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
MY145465A (en) | Diaminopyrimidines as p2x3 and p2x2/3 antagonists. | |
EA201101672A1 (en) | SUBSTITUTED DERIVATIVES OF AMINOISAL ACID AS NEPRILISIN INHIBITORS | |
EA201290237A1 (en) | KINASE INHIBITORS | |
TW200633704A (en) | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library | |
RU2009117642A (en) | APPLICATION OF SPYROXYNDOLIC COMPOUNDS AS A THERAPEUTIC MEDICINES | |
AR120896A1 (en) | PYRIDAZINIL-THIAZOLCARBOXAMIDE COMPOUNDS AS DGKz INHIBITORS | |
AR115985A1 (en) | PIRAZINE COMPOUNDS AND USES OF THEM | |
AR065092A1 (en) | COMBINATION THERAPY WITH ANGIOGENESIS INHIBITORS | |
BRPI0509359A (en) | pyridyl substituted porphyrin compounds and methods of using these | |
RU2009110442A (en) | CONDENSED IMIDAZOLE DERIVATIVES FOR TREATMENT OF DISORDERS MEDIATED BY ALDOSTEROSYNTHASE AND / OR 11-BETA-HYDROXYLASE, AND / OR AROMATASE | |
PE20210176A1 (en) | ARGINASE INHIBITORS AND THEIR METHODS OF USE | |
AR074072A1 (en) | COMPOSITE OF IMIDAZOL -PIPERIDIN -PIRROL-PIRIMIDIN-6-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT MULTIFORM GLIOBLASTOMA | |
RU2020131012A (en) | 7-SUBSTITUTED SULFONIMIDOILPURINONE COMPOUNDS AND THEIR DERIVATIVES FOR THE TREATMENT AND PREVENTION OF LIVER CANCER | |
Govdi et al. | Betulonic acid–peptide conjugates: Synthesis and evaluation of anti-inflammatory activity | |
Middlemiss et al. | A medicinal chemistry case study: an account of an angiotensin II antagonist drug discovery programme | |
JP2019503356A5 (en) | ||
RU2013145869A (en) | COMBINATION OF ANTI-CLASTERIN OLIGONUCLEOTIDE WITH HSP90 INHIBITOR FOR TREATMENT OF PROSTATE CANCER | |
AR050043A1 (en) | METHODS TO IMPROVE BIODISPONIBILITY AND PHARMACEUTICAL COMPOSITION FOR CARDIOVASCULAR DISORDERS | |
JP2017529386A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |